RSS

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

October 6, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

October 4, 2021
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19

SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19

September 22, 2021
SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences

September 8, 2021
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

July 9, 2021
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

July 8, 2021